Semaglutide | Medical Weight Loss | Spokane Valley
Losing weight can feel like an uphill battle, especially when you’re doing everything right but still not seeing results. If you’re constantly hungry, low on energy, or stuck in cycles of losing and regaining weight, it’s time for a closer look. It’s time for root-cause weight loss.
At ShillMed, we take a comprehensive, medically guided approach to weight loss. Using advanced medications such as Semaglutide alongside a structured lifestyle program, we help patients achieve meaningful weight loss — and maintain it long-term. Under the care of Dr. Shill, your plan is built around your biology, your habits, and your goals. This page has been reviewed by Dr. Shill.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist, also known as a medication that mimics a naturally occurring hormone in your body that regulates appetite, blood sugar, and digestion.
It works by targeting the systems that often make weight loss difficult, including hunger signaling and metabolic control.
Semaglutide supports weight loss by:
-
Reducing appetite and helping you feel satisfied with less food
-
Slowing gastric emptying, which keeps you fuller longer
-
Improving blood sugar regulation and insulin sensitivity
-
Decreasing cravings, especially for high-calorie and processed foods
Unlike traditional diets that rely on willpower alone, Semaglutide works with your body’s natural physiology to make weight loss more achievable. At ShillMed, we use Semaglutide as part of a broader strategy, never as a standalone solution.
A Smarter Approach to Medical Weight Loss
Semaglutide is popular within the weight loss world because of its effectiveness. But medication alone is not the full answer. Lasting weight loss requires addressing the behaviors, habits, and systems that influence your health.
That’s why ShillMed integrates Semaglutide into a complete, personalized medical weight loss program. Your treatment plan is based on a detailed understanding of your metabolism, appetite patterns, and lifestyle factors.
For some patients, Semaglutide is the ideal starting point. For others, it may be combined with or transitioned alongside other medications such as Qsymia, depending on how your body responds. This flexibility ensures your plan evolves with you.
A Total Lifestyle Program for Lasting Results
Medication can help initiate weight loss, but long-term success depends on building a foundation that supports your results. That’s why every patient at ShillMed is guided through a complete lifestyle program designed to reinforce and maintain progress.
Don’t Just Lose Weight: Keep It Off
One of the most common frustrations in weight loss is regain. Many people lose weight temporarily, only to see it return when the plan ends.
At ShillMed, we focus on long-term success by addressing the root causes of weight gain. Semaglutide helps regulate appetite and metabolism, but the lifestyle program ensures those changes are supported over time.
Why a Team-Based Approach Matters
Weight loss is influenced by multiple systems in your body, including hormones, metabolism, and brain chemistry. It’s also shaped by your habits, environment, and daily routine. That’s why a team-based approach is so effective.
At ShillMed, you’re supported by a coordinated system that adapts as you progress. This allows for:
-
Ongoing adjustments to your medication and lifestyle plan
-
Consistent accountability to keep you on track
-
Early intervention when challenges arise
-
Encouragement and guidance throughout your journey
You’re not doing this alone, and that makes a real difference.
Dr. Shill’s Personalized Approach to Medical Weight Loss
Dr. Shill is one of the most in-demand weight loss doctors in the Spokane area. He understands that weight loss is not one-size-fits-all. Every patient has a different history, different challenges, and different goals.
Your journey begins with a comprehensive evaluation that looks beyond the scale. From there, your plan is built around your specific needs, whether that includes Semaglutide, other medications, or a combination of therapies. This personalized approach leads to more effective results and a better overall experience.
Hormone Therapy and Weight Loss
Get Started with Medical Weight Loss in Spokane Valley
You don’t have to keep navigating weight loss on your own. With the right medical support and a comprehensive plan, lasting results are possible.
At ShillMed, we combine Semaglutide with a structured lifestyle program to help you lose weight, improve your health, and keep the weight off for good. Get started with medical weight loss in Spokane Valley today and discover whether Semaglutide is right for you.
Critical Safety Information
Black Box Warning: Semaglutide (specifically brand names like Ozempic/Wegovy) carries a boxed warning regarding the risk of thyroid C-cell tumors. This should be explicitly mentioned so patients can discuss their family history (e.g., Medullary Thyroid Carcinoma or MEN 2 syndrome) with the physician.
Serious Gastrointestinal Risks: While it mentions "changes in digestion," it omits potential severe side effects such as pancreatitis, gallbladder disease, and the risk of bowel obstruction/ileus, which are recognized clinical risks.
Dehydration/Kidney Risk: Due to the risk of nausea and vomiting, patients are at higher risk for dehydration, which can lead to acute kidney injury—a critical safety point not mentioned here.
Injection Site Reactions: As an injectable medication, patient education usually includes information on injection site reactions, which is absent from this FAQ.
References:
Clinical Efficacy (STEP-1 Trial) Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183 Cited by: 6182
PubMed
Multidisciplinary Approach to Weight Maintenance Marchesini, G., Montesi, L., El Ghoch, M., Brodosi, L., Calugi, S., & Dalle Grave, R. (2016). Long-term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 9, 37. https://doi.org/10.2147/dmso.s89836 Cited by: 523
Dove Medical Press
Cardiovascular Outcomes (SELECT Trial) Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2022). Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity, 31(1), 111–122. https://doi.org/10.1002/oby.23621 Cited by: 127
PubMed
Safety Profile and Adverse Effects Kommu, S. (n.d.). Semaglutide. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK603723/ Cited by: 44
Clinical Review of GLP-1 Receptor Agonists Salvador, R. (n.d.). Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11944337/ Cited by: 39